Categories
Change Password!
Reset Password!
Lasmiditan is a potent therapeutic option for managing migraines with the flexibility to tailor doses according to individual requirements, elevating treatment outcomes.
Fresh insights from a retrospective examination of the open-label extension (OLE) of the CENTURION trial illuminate the treatment patterns and outcomes concerning the long-term usefulness of Lasmiditan for migraineurs.
The analysis presented in ‘The Journal of Headache and Pain’ encompassed data from 445 patients who tackled at least one migraine episode with Lasmiditan during the OLE, with 72.1% completing the study. Among them, 47% adhered to the initial 100 mg dose, while others fine-tuned their dosage levels to suit their needs, with such adjustments proving advantageous in enhancing effectiveness or tolerability.
First, the Lasmiditan dose was 100 mg, with later dose adjustments to 50 mg or 200 mg permitted at the investigator’s discretion. Patient and clinical characteristics were summed by the dosing pattern and the status of completion. Safety was assessed considering the adverse events (AE) by the number of doses.
Of note, individuals who persisted with Lasmiditan, despite experiencing adverse events (AEs), witnessed a decline in AE occurrence over time. Furthermore, those who tweaked their dosage levels reported improvements both clinically and in self-reported assessments. Nevertheless, the group receiving the 100 mg dose boasted the highest ratio of patients noticing betterment in their migraine condition.
Significantly, patients who opted for dosage adjustments demonstrated higher completion rates compared to those maintaining the 100-mg dose, hinting at enhanced tolerance or effectiveness with personalized dosing. Crucially, the concurrent usage of triptans with Lasmiditan did not heighten AE frequency, noted the study authors.
The Journal of Headache and Pain
Long-term treatment with Lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trial
Mika Komori et al.
Comments (0)